HomeAI · summaries
Storia in 7 fonti
Zenbexus-led combination nabs FDA’s first CELMoD therapy approval in multiple myeloma
The FDA has granted accelerated approval to the first cereblon E3 ligase modulation therapy for patients with multiple myeloma.Iberdomide (Zenbexus, Bristol Myers Squibb), in combination with daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen) and dexamethasone, received approval for adults with multiple myeloma who underwent at least one prior line of therapy including a proteasome
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
saudigazette.com.sa
SFDA becomes first regulatory authority globally to approve registration of 'ZENBEXUS' to treat multiple myeloma in adults
The Saudi Food and Drug Authority (SFDA) has approved the registration of ZENBEXUS (iberdomide) for the treatment of adult patients with relapsed or refractory multiple myeloma in…
- ·
medpagetoday.com
FDA Approves First CELMoD Drug for Multiple Myeloma
Iberdomide indicated as part of combination regimen for relapsed or refractory disease
